We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
-5.17%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$6.16B
AUM Growth
-$821M
(-12%)
Cap. Flow
-$392M
Cap. Flow
% of AUM
-6.36%
Top 10 Holdings %
Top 10 Hldgs %
16.27%
Holding
911
New
217
Increased
113
Reduced
100
Closed
202
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$100M |
| 2 |
ZNGA
ZYNGA INC. CL A COMMON
ZNGA
|
+$97M |
| 3 |
Lam Research
LRCX
|
+$85.4M |
| 4 |
Boston Scientific
BSX
|
+$79.4M |
| 5 |
Merck
MRK
|
+$67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$145M |
| 2 |
ASML
ASML
|
+$119M |
| 3 |
Qorvo
QRVO
|
+$89M |
| 4 |
Microsoft
MSFT
|
+$82.9M |
| 5 |
Intuitive Surgical
ISRG
|
+$75.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.56% |
| 2 | Technology | 29.01% |
| 3 | Industrials | 8.79% |
| 4 | Communication Services | 5.99% |
| 5 | Financials | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Teleflex
TFX
$6.06B
| $14.5M | 0.24% |
40,921
-20,100
| -33% | -$6.62M |
|
127
Zymeworks
ZYME
$1.73B
| $14.5M | 0.24% |
2,216,062
+957,661
| +76% | +$8.53M |
|
128
Textron
TXT
$15.2B
| $14.5M | 0.24% |
194,927
-47,277
| -20% | -$3.41M |
|
|
AVDL
129
DELISTED
Avadel Pharmaceuticals
AVDL
| $14.5M | 0.23% |
2,116,029
-146,973
| -6% | -$1.01M |
|
130
Charter Communications
CHTR
$18.3B
| $14.2M | 0.23% |
+26,085
| New | +$15.3M |
|
|
SAIL
131
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
| $14.2M | 0.23% |
276,528
-24,659
| -8% | -$1.05M |
|
132
Outset Medical
OM
$94.9M
| $14.1M | 0.23% |
20,653
+5,253
| +34% | +$3.16M |
|
133
Keros Therapeutics
KROS
$198M
| $14M | 0.23% |
257,200
+180,988
| +237% | +$9.29M |
|
134
Electronic Arts
EA
$52.9B
| $14M | 0.23% |
110,464
-235,077
| -68% | -$30.6M |
|
135
Protagonist Therapeutics
PTGX
$8.83B
| $13.9M | 0.23% |
588,694
+95,707
| +19% | +$2.7M |
|
136
Henry Schein
HSIC
$10.2B
| $13.9M | 0.23% |
159,463
-470,352
| -75% | -$38.3M |
|
137
Thermo Fisher Scientific
TMO
$214B
| $13.7M | 0.22% |
23,271
+5,318
| +30% | +$3.05M |
|
138
Nice
NICE
$5.82B
| $13.7M | 0.22% |
+62,488
| New | +$15.1M |
|
139
Exelixis
EXEL
$14.3B
| $13.6M | 0.22% |
601,800
| – | – |
|
|
VG
140
DELISTED
Vonage Holdings Corporation
VG
| $13.6M | 0.22% |
670,197
+121,497
| +22% | +$2.49M |
|
141
CrowdStrike
CRWD
$214B
| $13.5M | 0.22% |
+238,052
| New | +$11.1M |
|
|
SWTX
142
DELISTED
SpringWorks Therapeutics
SWTX
| $13.2M | 0.21% |
233,210
-9,190
| -4% | -$526K |
|
143
Ascendis Pharma A/S
ASND
$16B
| $13.1M | 0.21% |
112,012
-112,437
| -50% | -$13M |
|
144
Intel
INTC
$510B
| $13.1M | 0.21% |
+264,284
| New | +$13.1M |
|
145
Penumbra
PEN
$12.7B
| $13M | 0.21% |
58,345
-14,287
| -20% | -$3.17M |
|
146
Flex
FLEX
$45B
| $12.9M | 0.21% |
919,734
-894,406
| -49% | -$11.4M |
|
147
HealthEquity
HQY
$8.73B
| $12.8M | 0.21% |
190,180
+127,188
| +202% | +$6.87M |
|
148
Zai Lab
ZLAB
$2.07B
| $12.8M | 0.21% |
+291,517
| New | +$14.1M |
|
149
Sana Biotechnology
SANA
$977M
| $12.8M | 0.21% |
1,551,940
+1,069,234
| +222% | +$8.64M |
|
|
PRO
150
DELISTED
PROS Holdings
PRO
| $12.7M | 0.21% |
+381,187
| New | +$11.7M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q1 2022 Portfolio in Review
As of Q1 2022, Woodline Partners held 911 positions worth $6.16B, down 12% from $6.98B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Woodline Partners withdrew a net $392M in Q1 2022, closing 202 positions and reducing 100 holdings. Its most notable exit was AbbVie, an estimated $145M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.
Against the trend, Woodline Partners opened a new position in ZYNGA INC. CL A COMMON worth $102M.
- Woodline Partners's largest Q1 2022 buy was ZYNGA INC. CL A COMMON: 11,039,458 shares worth $102M.
- Woodline Partners added most to Seagen Inc. Common Stock in Q1 2022, an estimated $100M increase.
- Woodline Partners's biggest Q1 2022 reduction was Qorvo, cutting an estimated $89M.
- Woodline Partners fully exited AbbVie in Q1 2022, selling an estimated $145M.
- Woodline Partners's ten largest holdings make up 16% of its $6.16B portfolio in Q1 2022.
- Woodline Partners opened 217 new positions and closed 202 in Q1 2022.
- Woodline Partners's portfolio value fell 12% quarter-over-quarter to $6.16B.
Based on Woodline Partners's 13F filing for Q1 2022, filed 16 May 2022.